Fully guaranteed rights issue
Fully guaranteed rights issue
DISCLAIMER – IMPORTANT
Access to the information and documents contained in this section of Scandion Oncology A/S’ (the “Company”) website relating to the contemplated rights issue by the Company (collectively the “Materials”) may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such Materials. The Materials are not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States”), Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction (the “Excluded Territories”) , and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of the Company in the Excluded Territories where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.
The information contained herein, and in the Materials, does not constitute an offer or solicitation to buy or subscribe for securities, including shares of the Company (the “Shares”) or pre-emptive rights (the “Pre-emptive Rights”) to subscribe for such Shares, in the United States. The securities mentioned herein, and in the Materials, may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“Securities Act”), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities, including the Pre-emptive Rights and Shares, mentioned herein and in the Materials in the United States or to issue a public offering of such securities in the United States. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
In any relevant member state of the European Economic Area, with the exception of Sweden (each a “Relevant Member State”), any offering of securities, including Pre-emptive Rights and Shares, will be made only on conditions that it does not lead to requirements for drawing up of prospectuses in such countries in accordance with the Prospectus Regulation. In any Relevant Member State other than Sweden, the Materials are addressed only to, and is only directed at, investors in such Relevant Member State that fulfil the criteria for exemption from the obligation to publish a prospectus, including Qualified Investors, or otherwise on the condition that the access to the Materials does not lead to a requirement for drawing up of a prospectus in such Relevant Member States in accordance with the Prospectus Regulation.
All persons residing outside of Sweden who wish to have access to the information and Materials contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been obtained outside Sweden. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
The contents of this website are not to be incorporated into, or construed to form part of, any of the Materials included herein. Except as otherwise explicitly stated herein as applicable to them, no information included on this website should be used by investors in forming their investment decision as to an investment in the Pre-emptive Rights or Shares.
The use of this section of the website is subject to Swedish law and any disputes arising out of or regarding this section of the website is subject to Swedish law and the exclusive jurisdictions of the Swedish courts.
I therefore certify that:
I am resident and physically located outside the Excluded Territories and I am not acting on behalf of someone who is a resident of or located in any of these jurisdictions. I agree that I will not transmit or otherwise send any materials contained in this website (either in whole or in part) to any person resident of or located in the Excluded Territories.
I am resident and physically present
(a) in Sweden or
(b) outside the Excluded Territories and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company.
I have read, understand and agree to comply with all of the restrictions set forth above.
The information contained in this section of Scandion Oncology (the “Company”) website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from, the United States of America, including its territories and possessions, any state of the United States and the District of Columbia (the “United States”), Canada, Australia and Japan or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.Go to home page
Bo Rode Hansen, CEO
T: +45 38 10 20 17
Klarabergsviadukten 63, 9 tr
101 23 Stockholm
Phone: +46 8 511 68 000
Norra Vallgatan 64
211 22 Malmö
Phone: + 46 406151410